Home » Stocks » ALNA

Allena Pharmaceuticals, Inc. (ALNA)

Stock Price: $1.11 USD -0.04 (-3.48%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $1.13 +0.02 (1.80%) May 6, 5:27 PM
Market Cap 62.43M
Revenue (ttm) n/a
Net Income (ttm) -32.85M
Shares Out 32.51M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $1.11
Previous Close $1.15
Change ($) -0.04
Change (%) -3.48%
Day's Open 1.13
Day's Range 1.08 - 1.15
Day's Volume 782,315
52-Week Range 1.02 - 3.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEWTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-cla...

4 weeks ago - GlobeNewsWire

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

4 weeks ago - GlobeNewsWire

-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyper...

1 month ago - GlobeNewsWire

NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...

2 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALRN, MBIO, MCHX, MDWD, OBSV, RWLK
3 months ago - InvestorPlace

-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -- -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --

3 months ago - GlobeNewsWire

Is (ALNA) Outperforming Other Medical Stocks This Year?

3 months ago - Zacks Investment Research

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

4 months ago - GlobeNewsWire

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% po...

Other stocks mentioned: RGLS
4 months ago - GuruFocus

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

5 months ago - GlobeNewsWire

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

5 months ago - GlobeNewsWire

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

5 months ago - GlobeNewsWire

-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Concept...

5 months ago - GlobeNewsWire

NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

5 months ago - GlobeNewsWire

-- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperoxal...

5 months ago - GlobeNewsWire

NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

6 months ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

NEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...

7 months ago - GlobeNewsWire

-- Extends Allena’s Cash Runway into 4Q 2021 -- -- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASD...

7 months ago - GlobeNewsWire

NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral ...

8 months ago - GlobeNewsWire

-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –-

9 months ago - GlobeNewsWire

NEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

9 months ago - GlobeNewsWire

NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

9 months ago - GlobeNewsWire

NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

9 months ago - GlobeNewsWire

NEWTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

11 months ago - GlobeNewsWire

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 --

11 months ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) –

1 year ago - GlobeNewsWire

Allena Pharmaceuticals: Rating This Stock A Buy

1 year ago - Seeking Alpha

Allena Demolished: Weak Phase III And Dismal Prognosis

1 year ago - Seeking Alpha

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria

1 year ago - GlobeNewsWire

Topline data from URIROX-1 expected in 4Q 2019 Topline data from URIROX-1 expected in 4Q 2019

1 year ago - GlobeNewsWire

NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral ...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type of kidney stone.

1 year ago - Seeking Alpha

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

About ALNA

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients wit... [Read more...]

Industry
Biotechnology
IPO Date
Nov 2, 2017
CEO
Louis Brenner
Employees
41
Stock Exchange
NASDAQ
Ticker Symbol
ALNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ALNA stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 530.63% from the latest price.

Price Target
$7.00
(530.63% upside)
Analyst Consensus: Buy